growth hormone peptide: Frequently asked questions

GHRP-6 is the correct choice. Its non-selective ghrelin receptor binding allows direct investigation of peripheral ghrelin effects including appetite regulation, gastric motility, and NPY cascade activation. GHRP-2's selectivity for GHS-R1a means it bypasses many peripheral ghrelin pathways, making it unsuitable for studies targeting ghrelin's role in hunger, digestion, or metabolic signaling outside the pituitary.

GHRP-2 produces 60–70% less cortisol co-secretion than GHRP-6 at matched doses. Switch to GHRP-2 if your protocol examines immune function, sleep quality, or muscle protein synthesis, all of which are suppressed by elevated cortisol. GHRP-6's cortisol spike disrupts circadian rhythm studies and introduces inflammation markers that mask primary outcomes in immune response research.

Use GHRP-2 exclusively. GHRP-6's ghrelin pathway activation will increase food intake and introduce an uncontrolled variable. GHRP-2 delivers equivalent GH pulses without the appetite spike, preserving stable caloric intake baselines critical to metabolic or body composition studies. Protocols examining fat oxidation, insulin sensitivity, or lean mass retention cannot tolerate the confounding hunger effect GHRP-6 produces.

Investigate alternative stressors in the research protocol. Ipamorelin acetate does not elevate cortisol through receptor binding pathways. If plasma cortisol rises during an ipamorelin study, the cause is external: handling stress in rodent models, circadian disruption from study scheduling, concurrent administration of other compounds, or baseline HPA axis dysregulation in the subject population. Run a vehicle-only control group receiving bacteriostatic water injections on the same schedule. If cortisol rises in that group as well, the injection procedure itself is the stressor. If cortisol remains stable in controls but rises in the ipamorelin group, verify peptide purity and confirm the supplied compound is actually ipamorelin (mass spectrometry or HPLC confirmation from the supplier).

Discard the vial immediately. Cloudiness or visible particles indicate protein aggregation, microbial contamination, or peptide degradation. Ipamorelin acetate in solution should remain clear and colorless throughout the 28-day use window when stored at 2–8°C. Aggregation occurs when peptide chains misfold and clump together, which happens if the vial was shaken during reconstitution, exposed to temperatures above 25°C, or contaminated during multi-dose draws. Do not attempt to filter or use a cloudy solution. Aggregated peptides lose receptor binding activity and may trigger immune responses in animal models.

Verify three variables before concluding the peptide is inactive: dosage accuracy, injection timing relative to endogenous somatostatin peaks, and concurrent use of compounds that suppress GH secretion. GH response to GHRH analogs is blunted when somatostatin tone is elevated—this occurs immediately post-meal (especially after high-carbohydrate intake), during hyperglycemia, and during chronic caloric surplus. Research protocols achieving maximal GH response administer CJC 1295 no DAC in a fasted state (minimum three hours post-meal) or pair it with a GHRP to suppress somatostatin. If dosing and timing are correct but GH elevation remains absent, consider receptor downregulation from prior exogenous GH exposure or contamination during reconstitution—both eliminate measurable response.

Switch to CJC 1295 with DAC or a different long-acting GHRH analog. The no-DAC version's 30-minute half-life makes it unsuitable for sustained IGF-1 studies unless administered multiple times daily. CJC 1295 with DAC produces continuous GH elevation for 6–8 days per injection, creating stable IGF-1 elevation throughout that window. Alternatively, consider combining no-DAC with a GHRP like Hexarelin in twice-daily dosing—the synergistic GH peaks produce cumulative IGF-1 elevation comparable to sustained-release formulations while preserving pulsatility. For research models prioritizing convenience over physiological fidelity, DAC formulations are appropriate; for models where pulsatile signaling matters, multiple daily no-DAC doses are necessary.

This suggests either off-target ghrelin receptor activation from a contaminated or mislabeled peptide, or the appetite change is unrelated to ipamorelin. Authentic ipamorelin acetate does not stimulate hunger. It selectively activates GHS-R1a in the pituitary without affecting peripheral ghrelin receptors in the hypothalamus or gastrointestinal tract that regulate appetite. If subjects show increased food intake, request a certificate of analysis (CoA) from the peptide supplier showing HPLC purity ≥98% and confirm the amino acid sequence via mass spectrometry. GHRP-6 is sometimes mislabeled as ipamorelin by low-quality suppliers, and GHRP-6 produces significant appetite stimulation. We maintain full third-party testing documentation for every peptide batch to eliminate this exact risk.

Discard the vial. Peptides in aqueous solution are highly temperature-sensitive—enzymatic degradation and protein aggregation accelerate significantly above 8°C. While lyophilized powder can tolerate brief ambient exposure (up to 72 hours at 25°C), reconstituted peptides must be refrigerated at 2–8°C immediately after mixing. A single six-hour room-temperature excursion reduces measured GH response by 30–60% in subsequent injections, as demonstrated in stability studies published in Pharmaceutical Research. Reconstituted CJC 1295 no DAC retains full potency for 28 days when refrigerated continuously; beyond that window, degradation becomes measurable.

Combination protocols are standard in GH research. The most common pairings involve CJC 1295 no DAC with growth hormone secretagogues (GHRPs like ipamorelin, GHRP-2, GHRP-6, or hexarelin) to achieve synergistic GH release. Administer both peptides simultaneously or within five minutes of each other—receptor activation must overlap temporally to suppress somatostatin and amplify the GH pulse. A secondary common combination involves CJC 1295 no DAC with BPC 157 Peptide or TB 500 Thymosin Beta 4 in tissue repair models studying whether GH-mediated anabolic signaling enhances collagen synthesis or wound healing rates. These peptides act on distinct receptor systems and can be reconstituted in the same syringe if administered immediately—do not pre-mix and store combined peptides, as interaction stability data does not exist for most combinations.

Verify storage conditions and peptide potency first. Diminished response is more often due to peptide degradation than receptor desensitization. Ipamorelin's short half-life and pulsatile exposure pattern should not cause receptor downregulation within typical study durations (12–16 weeks). If GH output drops, check reconstituted vial storage temperature (must remain 2–8°C), confirm the vial is used within 28 days of reconstitution, and test a fresh vial from a different batch. If the issue persists across batches and storage is confirmed correct, measure baseline IGF-1 and endogenous GH pulsatility. Some models develop compensatory somatostatin upregulation that blunts secretagogue response over time, though this is rare with ipamorelin compared to continuous GH exposure models.

Administer during daytime hours when studying isolated GH pulse effects independent of circadian rhythms. Endogenous GH secretion is minimal during waking hours, so daytime ipamorelin administration creates a clean experimental window where measured GH comes almost entirely from peptide stimulation rather than overlapping with natural nocturnal pulses. This approach is standard in pharmacokinetic studies measuring ipamorelin's dose-response curve or comparing GH output across different secretagogues. Evening administration (1 hour before sleep onset) amplifies the natural nocturnal GH surge and is preferred for studies investigating sleep quality, recovery, or metabolic parameters that depend on overnight GH exposure.

Do not use it—cloudiness indicates peptide aggregation or precipitation, which occurs when peptide bonds misfold and clump together. Aggregated peptides lose bioactivity and may introduce injection site reactions or inconsistent dosing. The most common cause is improper reconstitution technique—injecting water directly onto the lyophilized cake with force, or shaking the vial after adding bacteriostatic water. Prevent this by injecting water slowly down the vial wall and allowing the powder to dissolve passively at refrigeration temperature. If cloudiness appears in a properly reconstituted vial after several days of storage, temperature excursion above 8°C is the likely cause—verify your refrigerator maintains consistent 2–8°C range.

Verify reconstitution and storage first—hexarelin degrades rapidly if exposed to temperatures above 25°C or stored beyond 28 days post-reconstitution. If handling was correct, consider that prior GH secretagogue exposure within 48–72 hours can suppress subsequent hexarelin response due to residual receptor occupancy or depletion of pituitary GH stores. The GH response to hexarelin is also blunted in models with hypothalamic damage or genetic GH deficiency where pituitary somatotrophs are non-functional—hexarelin requires intact GH synthesis capacity to produce measurable pulses. Dose escalation is an option, but if doubling the dose produces no increase in GH, receptor desensitization or peptide degradation is the likely cause rather than insufficient dosing.

Administer a GH receptor antagonist (e.g., pegvisomant in large animal models) alongside hexarelin to block downstream GH signaling while preserving hexarelin's direct tissue effects mediated by GHS-R1a in peripheral organs. This approach isolates hexarelin's cardioprotective effects, its influence on inflammation markers via direct immune cell GHS-R1a activation, and its neuroprotective signaling in the CNS—all of which occur independently of systemic GH elevation. This experimental design is common in cardiovascular research where distinguishing GH-mediated from GHS-R1a-mediated effects is critical for mechanistic interpretation.

This is expected—receptor desensitization begins within 5–7 days of continuous daily administration. Switch to a pulsed protocol: administer hexarelin every 48–72 hours rather than daily. Studies show GHS-R1a receptor density recovers to near-baseline within 48 hours of hexarelin clearance, so spacing doses allows receptor re-expression between administrations. Alternatively, cycle hexarelin with a different GHS like ipamorelin or GHRP-2, which exhibit lower desensitization rates and act through slightly different signaling kinetics—this prevents complete receptor downregulation while maintaining GH axis stimulation.